Testosterone therapy may reduce non-alcoholic fatty liver disease in obese

According to a new study, testosterone therapy may reduce non-alcoholic fatty liver disease in obese men with functional hypogonadism and type-2 diabetes. Testosterone therapy may help obese men with functional hypogonadism and type-2 diabetes reduce the prevalence of non-alcoholic fatty liver disease (NAFLD), according to a study being presented at the 23rd European Congress of Endocrinology (e-ECE 2021), (http://www.ece2021.org). The […]